Certara Appoints Jon Resnick as New CEO

Certara ( (CERT) ) has provided an update.

On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, effective January 1, 2026. Resnick, who brings over 20 years of experience from IQVIA, will succeed William F. Feehery, who will step down on December 31, 2025, and serve as an advisor during the transition. The company reaffirmed its 2025 financial outlook, indicating stability and confidence in the leadership transition. Resnick’s appointment is expected to propel Certara’s growth and innovation in drug discovery and development, leveraging his extensive experience in healthcare strategy and operations.

The most recent analyst rating on (CERT) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Certara stock, see the CERT Stock Forecast page.

Spark’s Take on CERT Stock

According to Spark, TipRanks’ AI Analyst, CERT is a Neutral.

Certara’s overall stock score reflects a solid financial foundation and positive corporate events, but is tempered by technical analysis indicating bearish trends and a high P/E ratio suggesting overvaluation. The mixed results from the earnings call further contribute to a cautious outlook.

To see Spark’s full report on CERT stock, click here.

More about Certara

Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Average Trading Volume: 2,112,938

Technical Sentiment Signal: Sell

Current Market Cap: $1.46B

For an in-depth examination of CERT stock, go to TipRanks’ Overview page.